AHL
CYTK icon

Abel Hall LLC’s Cytokinetics CYTK Stock Holding History

Abel Hall LLC’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450K Buy
5,283
+1,233
+30% +$88.5K 0.08% 281
2026
Q1 		$267K Buy
4,050
+384
+10% +$24.4K 0.06% 467
2025
Q4 		$233K Buy
+3,666
New +$228K 0.05% 466

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abel Hall LLC's CYTK Position: Q2 2026 in Review

Abel Hall LLC increased its Cytokinetics (CYTK) stake by 30% in Q2 2026, buying an estimated $88.5K and bringing the position to 5,283 shares worth $450K. The position accounts for 0.08% of the portfolio, ranked #281.

Abel Hall LLC first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Abel Hall LLC held 5,283 shares of Cytokinetics worth $450K as of Q2 2026.
  • Abel Hall LLC bought 1,233 Cytokinetics shares in Q2 2026, an estimated $88.5K.
  • Cytokinetics made up 0.08% of Abel Hall LLC's portfolio in Q2 2026, its #281 holding.
  • Abel Hall LLC first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.